In the vascular endothelium, diverse cell surface receptors are coupled to the Ca2+/calmodulin-dependent activation of nitric oxide (NO) synthase. We now report that, in intact cultured endothelial cells, several drugs and agonists are associated with increased serine phosphorylation of the endothelial NO synthase. We biosyntheticaily labeled bovine aortic endothelial cells with [32PJorthophosphoric acid, exposed the cells to various drugs and hormones, and then immunoprecipitated the enzyme from cell extracts using a highly specific anti-peptide antibody. The marked endothelial NO synthase phosphorylation induced by bradykinin is maximal only after 5 min of agonist exposure and is stable for at least 20 min. Basal and agonist-induced phosphorylation of the NO synthase in endothelial cells is completely inhibited by the calmodulin antagonist compound W-7. We prepared subcel- nine-labeled NO synthase is now found in the cytosolic fraction, associated with a marked increase in the level of cytosolic enzyme phosphorylation. We propose that agonist-induced phosphorylation of NO synthase is associated with translocation of the enzyme from membrane to cytosol and may thereby regulate the biological effects of endothelial NO synthesis in situ.
endothelial NO synthase. We biosyntheticaily labeled bovine aortic endothelial cells with [32PJorthophosphoric acid, exposed the cells to various drugs and hormones, and then immunoprecipitated the enzyme from cell extracts using a highly specific anti-peptide antibody. The marked endothelial NO synthase phosphorylation induced by bradykinin is maximal only after 5 min of agonist exposure and is stable for at least 20 min. Basal and agonist-induced phosphorylation of the NO synthase in endothelial cells is completely inhibited by the calmodulin antagonist compound W-7. We prepared subcellular fractions of endothelial cells that had been biosyntheti- nine-labeled NO synthase is now found in the cytosolic fraction, associated with a marked increase in the level of cytosolic enzyme phosphorylation. We propose that agonist-induced phosphorylation of NO synthase is associated with translocation of the enzyme from membrane to cytosol and may thereby regulate the biological effects of endothelial NO synthesis in situ.
Nitric oxide (NO) is a ubiquitous intercellular signaling molecule and is synthesized in diverse mammalian tissues by a family of related NO synthase enzymes. In all tissues thus far characterized, the NO synthase isoforms share a common overall catalytic scheme for the oxidation of L-arginine to form NO plus L-citrulline and appear to share similar cofactor requirements (reviewed in refs. [1] [2] [3] . The different tissuespecific NO synthase isoforms subserve disparate biological functions in diverse mammalian cells and appear to be encoded by distinct genes (4) .
The endothelial NO synthase plays an important role in the control of blood pressure and platelet aggregation (5) . In bovine endothelial cells, the NO synthase is transiently activated by increases in intracellular calcium induced by the activation of diverse G-protein-coupled cell surface receptors, including bradykinin. Our analysis of the primary structure of the endothelial NO synthase cDNA identified consensus sequences for posttranslational modifications of the enzyme, including N-terminal myristoylation as well as phosphorylation (4) . We have recently shown that the endothelial
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NO synthase undergoes N-terminal myristoylation, and this covalent modification is essential for the association of the enzyme with the particulate subcellular fraction (6) . Some myristoylated proteins implicated in intracellular signaling pathways have been shown to regulated by reversible phosphorylation, and phosphorylation further appears to modulate their subcellular localization (reviewed in refs. 7 and 8) .
The deduced primary structures of NO synthase cDNAs encoding neural (9) and endothelial (4) enzyme isoforms have been noted to contain consensus sequences for phosphorylation by diverse protein kinases. The NO synthase purified from rat brain can be phosphorylated in vitro by numerous protein kinases, including protein kinase C, the cyclic AMPdependent protein kinase, as well as the calcium/calmodulin protein kinase II (10, 11 Proc. Natl. Acad. Sci. USA 90 (1993) 6253 against a synthetic NO synthase oligopeptide. This polyclonal antiserum was raised in rabbits against a synthetic peptide deduced from the sequence (4) of the endothelial NO synthase cDNA (PYNSSPRPEQHKSYK-C, corresponding to amino acid residues 599-614 plus a C-terminal C residue used to couple the peptide to maleimide-activated keyhole limpet hemocyanin). We have previously shown (ref. 6 ) that this immune serum is highly specific for immunoprecipitation of endothelial NO synthase and that immunoprecipitation of biosynthetically labeled protein is blocked by the unlabeled peptide. Following the isolation of immune complexes with protein A-Sepharose, the proteins were eluted by heating with SDS/PAGE sample buffer. The phosphorylated proteins were analyzed by SDS/PAGE on 7% polyacrylamide gels, followed by autoradiography and exposure on Kodak XAR film or the phosphorylated proteins were quantitated using a PhosPhorlmager (Molecular Dynamics). For subcellular fractionations, the cells were harvested by scraping in 50 mM Tris HCl, pH 7.4/0.1 mM EDTA/0.1 mM EGTA/2 mM 2-mercaptoethanol/50 mM NaF plus protease inhibitors and then sonicated to yield the cell lysate, which then was centrifuged at 100,000 x g for 1 hr, and the pellet (particulate fraction) was resuspended in buffer B; 5 volumes of buffer B was added to the supernatant (cytosol), and the individual subcellular fractions were immunoprecipitated as above. Biosynthetic labeling and immunoprecipitation from [35S]methionine-labeled endothelial cells were performed as described (6) .
Phosphopeptide Mapping and Phosphoamino Acid Analysis.
NO synthase immunoprecipitated from 32Pi-biosynthetically labeled BAEC was eluted from protein A-Sepharose and the samples were precipitated with 25% trichloroacetic acid and dissolved in 70% formic acid. Cyanogen bromide was added to a final concentration of 3 mg/ml, and the samples were incubated (24 hr, room temperature; ref. 12) and then lyophilized and dissolved by heating in SDS/PAGE sample buffer. The phosphopeptides were resolved on SDS/PAGE using a 15% polyacrylamide gel. Tryptic phosphopeptide mapping of the phosphorylated immunoprecipitated NO synthase was performed essentially as described (13) . After oxidizing the samples with performic acid, they were digested with trypsin overnight at 37°C, spotted on thin-layer cellulose plates (Merck), electrophoresed using the Hunter thin-layer electrophoresis apparatus (kindly provided by Michael Lu at Brigham and Women's Hospital) in 50 mM ammonium bicarbonate at pH 8.9 (1000 V, 45 min), and then subjected to ascending chromatography overnight in 1-butanol/pyridine/ acetic acid/H2O (750:500:150:600), followed by autoradiography. For phosphoamino acid analysis, the NO synthase immunoprecipitated from 32P,-labeled BAECs was incubated with 6 M HCl for 1 hr at 110°C, lyophilized, and then subjected to two-dimensional thin-layer electrophoresis exactly as described (13). acid and then exposed for 5 min to ionomycin (10 ,M), bradykinin (10 ,uM) , sodium nitroprusside (10 uM), or thrombin (1 unit/ml).
Immunoprecipitation was carried out as described in the text with preimmune serum (p) or immune serum (i) directed against the endothelial NO synthase; migrations of molecular mass markers are noted. The results shown above are representative of eight similar experiments.
level ofbasal phosphorylation ofthe endothelial NO synthase associated with treatment of endothelial cells with the calcium ionophore ionomycin or with the NO-liberating drug sodium nitroprusside, but the most striking increase in NO synthase phosphorylation was seen with the receptor agonist bradykinin. The agonist thrombin is without effect, consistent with prior observations that thrombin responses are lost early in the passage of cultured bovine endothelial cells (15) . In most experiments, the level of basal phosphorylation is low relative to the striking increase seen with drug or agonist treatment. However, the level of basal phosphorylation (in the absence of added compounds) and the degree of stimulation with drug treatment varied somewhat from experiment to experiment; yet, in 15 experiments, bradykinin consistently increased NO synthase phosphorylation between 2-and 8-fold relative to levels of basal phosphorylation. We chose to characterize the response to bradykinin in greater detail because it has the most marked effect on NO synthase phosphorylation in BAECs and also because bradykinin appears to be an important endogenous activator of NO synthase in the vasculature (5) .
Time Course of Phosphorylation. The time course of NO synthase phosphorylation by the agonist bradykinin is shown in Fig. 2 . Following the addition of bradykinin (10 ,M) to identically cultured 32P1-labeled BAECs in adjacent wells of RESULTS Agonist-Induced Phosphorylation of Endothelial NO Synthase. Fig. 1 shows the results of an experiment in which BAECs were biosynthetically labeled with 32p,, exposed to drugs or agonists for 5 min, immunoprecipitated with an anti-NO synthase antibody, and analyzed by SDS/PAGE and autoradiography. This approach resulted in the immunoprecipitation of a 135-kDa protein by immune serum, with no specific phosphoproteins precipitated by the preimmune serum. The molecular mass of this major phosphoprotein is identical to that of the cloned (4) or purified (14) Fig. 3A) , treated with cyanogen bromide, and analyzed by SDS/PAGE on a 15% polyacrylamide gel followed by autoradiography. Labeling of the a single -28-kDa cyanogen bromide phosphopeptide is found in the absence or presence of added drug; as before, the most marked increase in phosphorylation is seen following bradykinin treatment. There was no significant increase in phosphorylation seen with the adenylate cyclase activator forskolin nor with 8-bromoguanosine 3',5'-cyclic monophosphate over the time course of these experiments. Phorbol 12-myristate 13-acetate and sodium nitroprusside each caused an increase in phosphorylation of this peptide. To more clearly delineate the site(s) of phosphorylation, twodimensional tryptic phosphopeptide mapping (13) was performed ( Fig. 3B ) after immunoprecipitating the NO synthase from 32P1-labeled endothelial cells exposed to different drugs and agonists. A single NO synthase tryptic phosphopeptide is seen after exposure to bradykinin, sodium nitroprusside, or calcium ionophore; the same peptide also appears to be labeled under basal conditions. Under all of these conditions, the labeled phosphoamino acid was identified as phosphoserine in analyses of acid hydrolysates of immunoprecipitated NO synthase using two-dimensional high-voltage electrophoresis using standard techniques (ref. 13 ; data not shown).
Effects of Protein Kinase Inhibitors. A wide variety of protein kinase inhibitors was assayed for their effects on basal and bradykinin-induced phosphorylation of the NO synthase in BAECs. Shown in Fig. 4 is the results of an experiment using the calmodulin antagonist compound W-7 (16) and the protein kinase C inhibitor H-7 (17). The autoradiogram shown is intentionally overexposed to document that W-7 treatment completely abrogates basal and bradykinin-induced phosphorylation of the NO synthase. Other protein kinase inhibitors were assayed under their optimal conditions (see refs. [16] [17] [18] [19] , including the protein kinase C inhibitors H-7 (see Fig. 4 ) and sphingosine (20 ,uM) , the myosin light chain kinase inhibitor ML-9 (10 uM), the calmodulin kinase II inhibitor KN-62 (50 ,uM), and the cyclic For each plate, the site where the sample was applied is circled and the single labeled phosphopeptide spot is noted by an arrow. The cathode (-) and anode (+) positions are noted for the first-dimension electrophoresis, and ascending chromatography was then performed, after which time the plate was dried and exposed to XAR film for 7-10 days using an intensifying screen. This experiment was repeated three times with identical results. following exposure to bradykinin, the fraction of NO synthase immunoprecipitated in BAEC cytosol markedly increases, to 50%o of the total enzyme present. This increase in cytosolic NO synthase induced by bradykinin is not seen when the endothelial cells are treated with compound W-7 (data not shown).
A markedly different subcellular localization of the NO synthase is seen following biosynthetic labeling of BAECs with 32P1, as shown in Fig. 5 Lower. There is a significant increase in NO synthase phosphorylation in BAEC lysates followini bradykinin treatment, as we have documented above. Importantly, when the control 32Pi-labeled BAECs are fractionated into cytosolic and particulate fractions, the greatest proportion (80%) of the phosphorylated NO synthase is seen in the cytosol ( 
DISCUSSION
This study establishes that the endothelial NO synthase undergoes phosphorylation in response to treatment of bovine endothelial cells with diverse drugs and agonists. Agents that increase NO synthase activity are associated with increased phosphorylation of the enzyme. However, several features of NO synthase phosphorylation in endothelial cells would lead us to propose that enzyme phosphorylation is associated with deactivation of the enzyme. The phosphorylation of NO synthase induced by sodium nitroprusside, an agent that liberates NO, may suggest that the enzyme's product may lead to its phosphorylation and serve as a negative feedback to enzyme activity. Indeed, enzymatic activity of the neural NO synthase is inhibited by NO (via incompletely understood mechanisms) in cerebellar cytosol preparations (20) . Most importantly, the time course of NO synthase phosphorylation documented in these studies is markedly slower than that of enzyme activation in intact endothelial cells, as has been established in several laboratories using diverse experimental approaches (5). For example, using a highly selective NO electrode, Malinski and Taha (21) have shown that bradykinin treatment of BAECs results in activation of NO synthesis within seconds, and enzyme activity returns to baseline within 5 min. In contrast, phosphorylation ofNO synthase in endothelial cells in response to bradykinin is maximal only after 5 min of agonist exposure and persists for at least 20 min, long after bradykinin-induced enzyme activation has decayed. Phosphorylation of recombinant neural NO synthase in transfected cells apparently is associated with a decrease in enzyme activity (10) , and in vitro phosphorylation of the purified brain NO synthase by diverse protein kinases has been associated with decreases in enzyme activity as reported by some laboratories (Solomon Snyder, personal communication) but not by others (11) .
We found that the endothelial NO synthase is phosphorylated only on serine, and the same NO synthase tryptic phosphopeptide is identified following treatment of endothelial cells with bradykinin, sodium nitroprusside, or calcium ionophore as well as under basal conditions. This finding suggests that diverse signaling pathways may lead to the regulation of NO synthase phosphorylation at a single specific serine residue. Because of the pleiotropic effects of these different drugs, and the existence of multiple interacting signal transduction pathways within the cell, it cannot be stated with confidence that the effects of these different drugs involve activation of distinct protein kinases that share the same recognition site on the NO synthase or whether a common kinase is activated by these different drug treatments.
Our results, obtained with NO synthase phosphorylated in intact endothelial cells, contrast with the identification of distinct serine tryptic phosphopeptides (10) and the identification of phosphothreonine (11) following treatments of purified neural NO synthase by different protein kinases in vitro. These results may reflect intrinsic differences in the regulation by phosphorylation of different NO synthase isoforms or may be the result of the differences in experimental conditions. The challenges of obtaining sufficient quantities of pure endothelial NO synthase from cultured endothelial cells preclude the analysis of in vitro phosphorylation experiments for this isoform. We are hopeful that the development Biochemistry: Michel et al.
Om`opolm of heterologous recombinant protein expression systems for production of endothelial NO synthase will permit the correlation of our observations on enzyme phosphorylation in situ with those obtained in purified systems and allow the definitive assignment of the specific phosphorylated serine residue.
The striking inhibition ofbasal and bradykinin-induced NO synthase phosphorylation seen with the calmodulin antagonist W-7 may reflect one of several mechanisms. It may be that a calmodulin-dependent protein kinase is involved in NO synthase phosphorylation, and this activation of this kinase is inhibited by W-7. An equally plausible and nonexclusive hypothesis is that it is the calmodulin-liganded form of NO synthase that comprises the substrate for phosphorylation by protein kinase, and the inhibition of calmodulin by W-7 thereby blocks the formation of the appropriately liganded NO synthase-calmodulin substrate required for effective phosphorylation. Reconstitution experiments with purified components will allow these possibilities to be distinguished. There were no marked effects on NO synthase phosphorylation using inhibitors of protein kinase C, cyclic AMPdependent protein kinase, and calcium/calmodulin kinase II. The interpretation of these data is subject to the limitations inherent in drawing conclusions based on negative results. Nevertheless, it is tempting to speculate that the endothelial NO synthase may undergo phosphorylation by a protein kinase distinct from those listed above.
These studies suggest that the association of the endothelial NO synthase with the particulate subcellular fraction may be dynamically regulated by agonist-induced phosphorylation. There is a striking analogy with the MARCKS protein (myristoylated alanine-rich C-kinase substrate), a calmodulin-binding myristoylated protein that translocates from plasma membrane to cytosol upon phosphorylation by protein kinase C (8, 9) . To our knowledge, the endothelial NO synthase is the only NO synthase isoform thus far characterized that undergoes N-terminal myristoylation, and this myristoylation of the endothelial isoform is essential for its association with the particulate subcellular fraction in endothelial cells (6) . It seems plausible that the membrane association of the endothelial isoform may play a role in signal transduction.
The intracellular translocation of the endothelial NO synthase may have important implications for the regulation of the biological activity of the NO produced by endothelial cells. The lability of NO once it is formed and the tendency of NO to form adducts with other biomolecules (22) suggest that the intracellular compartment in which NO is synthesized may be an important determinant of the biological consequences of its synthesis. Dynamic alterations in the activity and intracellular localization of endothelial NO synthase by phosphorylation may add another level of complexity to understanding the mechanisms involved in the regulation of endothelial function in disease states.
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